Teva Pharmaceutical Industries (TEVA) Gross Margin (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Gross Margin came in at 51.98% in Q2 2026, up 164.0% YoY from 19.69% in Q2 2025, and up 4.96% on a QoQ basis from 49.52% in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Gross Margin (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Gross Margin data on file, last reported at 51.98% in Q2 2026.
- Quarterly Gross Margin rose 164.0% year-over-year to 51.98% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 52.47% (down 144.0% YoY) and the FY2025 annual result came in at 51.79%, up 305.0% from the prior year.
- Gross Margin advanced to 51.98% in Q2 2026, from 49.52% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 73.14% in Q4 2024 to a low of 43.21% in Q1 2023.
- A 5-year average of 50.24% and a median of 48.42% in 2024 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2024 — Gross Margin jumped 1893 bps — and 2025, when it sank 1676 bps.
- Tracing TEVA's Gross Margin over 5 years: stood at 45.57% in 2022, then advanced by 19 bps to 54.21% in 2023, then soared by 35 bps to 73.14% in 2024, then dropped by 23 bps to 56.38% in 2025, then dropped by 8 bps to 51.98% in 2026.
- The last three Gross Margin figures came in at 51.98% (Q2 2026), 49.52% (Q1 2026), and 56.38% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 51.98% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 42.63% |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 66.66% |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 87.30% |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 38.77% |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 97.58% |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 58.33% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 80.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.98% |
| Mar 31, 2026 | 49.52% |
| Dec 31, 2025 | 56.38% |
| Sep 30, 2025 | 51.43% |
| Jun 30, 2025 | 50.34% |
| Mar 31, 2025 | 48.24% |
| Dec 31, 2024 | 73.14% |
| Sep 30, 2024 | 49.58% |
| Jun 30, 2024 | 48.61% |
| Mar 31, 2024 | 46.37% |
| Dec 31, 2023 | 54.21% |
| Sep 30, 2023 | 48.08% |
| Jun 30, 2023 | 46.31% |
| Mar 31, 2023 | 43.21% |
| Dec 31, 2022 | 45.57% |
| Sep 30, 2022 | 46.43% |
| Jun 30, 2022 | 47.39% |
| Mar 31, 2022 | 47.53% |
| Dec 31, 2021 | 50.00% |
| Sep 30, 2021 | 46.15% |